Peter McWilliams, Ph.D.
Chief Executive Officer
Dr. McWilliams is the CEO of Glycomine. He was previously a Managing Director at Sanderling Ventures where he was responsible for its investment in Actimis Pharmaceuticals and, as CEO, led the company into the clinic and through to a successful exit via an acquisition by Boehringer Ingelheim. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in pre-clinical and clinical development including the anti-angiogenesis therapeutic, Avastin®. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Horacio Plotkin, M.D., F.A.A.P.
Chief Medical Officer
Dr. Horacio Plotkin has more than 30 years of experience in the rare diseases field, including 20 years of pediatric clinical experience and 10+ additional years of experience in drug development, having held positions at Genzyme, Enobia Pharma, Alexion Pharmaceuticals, Retrophin, Shire, PPD, Moderna and Selecta Biosciences. He is an Adjunct Associate Professor of Pediatrics and Orthopedic Surgery at the University of Nebraska School of Medicine and the founder and first Medical Director of the Pediatric Bone Diseases Program at Omaha Children’s Hospital. Dr. Plotkin earned his medical degree from the University of Buenos Aires School of Medicine. He completed a residency program in pediatrics, followed by four fellowships: pediatric endocrinology (J. P. Garrahan Pediatric Hospital, Buenos Aires), metabolic bone diseases (Metabolic Research Institute, Buenos Aires), endocrinology (Yale University School of Medicine, Connecticut) and pediatric metabolic bone diseases (Shriners Hospital for Children and Department of Surgery, McGill University, Montreal). Dr. Plotkin is a member of the scientific advisory board for several rare disease patient advocacy organizations and a member of the Advances in Therapeutics and Technology section at the American Academy of Pediatrics. He has authored eight chapters in medical textbooks and more than 50 scientific papers.
Kathlene Powell, M.S.
Senior Director CMC & Quality Operations
Kathlene Powell has over 28 years experience in Chemistry, Manufacturing, and Controls (CMC) and Quality management. She has held related management positions at Genentech, Covance Biotechnology Services, Inc., and Raptor Pharmaceutical, Inc. In a consulting capacity, Kathlene has served as the acting head of CMC and Quality functions in over ten organizations covering development through commercial manufacturing operations. Kathlene holds a BA degree in Chemistry from Doane College and a MS degree in Biochemistry from University of Missouri.
Lisa Koch-Hulle, RAC
Senior Director, Regulatory Affairs
Lisa Koch-Hulle has more than 25 years of regulatory affairs experience across multiple therapeutic areas and all stages of drug development, with approximately 15 years at the senior management level. Prior to Glycomine, Ms. Koch-Hulle held the position of Vice President of Regulatory Affairs and Clinical Operations at Light Sciences Oncology, and prior to that held the same position at La Jolla Pharmaceutical Company. Ms. Koch-Hulle has also served as a regulatory consultant to the pharmaceutical industry. Ms. Koch-Hulle holds regulatory certifications in US, European, and Global regulatory affairs, and is a former Chair of the RAPS European Certification Committee.
Teppei Shirakura, Ph.D.
Scientific Director, Chemistry
Dr. Shirakura is a Biophysicist with expertise in the development of hydrogel nanoparticles for targeted and controlled drug release for cancer therapy, diagnosis, and imaging. He leads the design and synthesis of nanotechnology-based platforms for intracellular delivery of Glycomine’s therapies. Teppei obtained a B.S. in Biophysics from Iowa State University and a Ph.D. in Biophysics from University of Michigan.
Director, Clinical Operations